BT-001
BT-001 is a multifunctional oncolytic virus from Invir.IO® platform.
Two specific “weapons” have been integrated into the vaccinia viral DNA: an anti-CTLA4 antibody , which was developed by BioInvent, and the cytokine GM-CSF, which triggers the body’s immune response.
Selectively destroying cancer cells
Derived from the Invir.IO® platform, our oncolytic viruses infect, specifically multiply and induce tumor cell lysis (or oncolysis).
These viruses also integrate anti-cancer weapons into their genome, enabling them to modulate the tumor microenvironment.
These different mechanisms lead to the destruction of tumor cells and the activation of the immune system, while preserving the patient’s own healthy cells.
BT-001 treatment turned “cold” tumors to “hot”
Preliminary data showed that BT-001 induces positive local, abscopal and sustained antitumoral activity in advanced refractory tumors.
BT-001 replicates in the tumor where the payloads are expressed with undetectable systemic exposure. BT-001 alone or in combination with pembrolizumab was well tolerated and showed first signs of efficacy with clinical responses in 2 of 6 patients who failed previous treatments, when given in combination with pembrolizumab.
These immune-mediated tumor shrinkages are consistent with the mechanistic hypothesis that BT-001, in combination with pembrolizumab, turns “cold” tumors into immunologically active ones.
Key news
about BT-001
Collaboration agreements
Transgene and BioInvent have entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the combination of the oncolytic virus BT-001 in combination with MSD’s anti-PD-1 checkpoint therapy KEYTRUDA® (pembrolizumab) in a Phase I/IIa clinical trial for the treatment of patients with solid tumors.
Additional ressources
Latest publications

- October 20, 2025Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors
- September 14, 2024Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
- April 11, 2022Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
- July 1, 20213D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
- November 9, 2020BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
- July 8, 2020Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
- June 22, 2020BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
- March 11, 2020BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
Latest press releases

- November 5, 2026First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer
- October 20, 2025Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
- October 13, 2025Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
- July 27, 2025Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
- September 14, 2024Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
- September 9, 2024Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
- July 22, 2024Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
- October 10, 2023Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
- May 25, 2023Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
- November 14, 2022Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
- June 28, 2022Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
- June 27, 2022Transgene and BioInvent announce positive progress for BT-001
- March 9, 2022Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022